Search

Skip to Search Results
  • Fall 2021

    Xu, Xia

    Glioblastoma (GBM) is the most common primary brain malignancy and has a dismal prognosis. Despite advanced therapies, including surgery and concurrent radiotherapy with temozolomide (TMZ), GBM patients only have a 14.6-month median survival time. This dismal outcome can be attributed to the...

1 - 1 of 1